Member Info for HedgeHogarth

The recent RNS and here on Bloomberg is the most comprehensive CBR update.

In March 2022, The Company filed a broad ranging seminal provisional patent application protecting its rights to the intellectual property ("IP") covering CBR. CBR is a novel platform technology that constitutes a new paradigm for treating viral infections.

Their legal advice will have given them the confidence to go more public with their work.

https://www.bloomberg.com/press-releases/2023-01-09/hemogenyx-pharmaceuticals-plc-announces-single-cbr-can-treat-multiple-viruses

What a great start for Hemo in FY23 and well deserved. Having been invested for a while now, its been great to see the progress - in line with expectations set by the company.

So what next i thought?

It was important to further to further prove the CBR concept to secure a great partnership - TICK, so I'm looking forward to an update

#Hemo have been actively pursuing a role in Biodefence - Given the current troubles in the world, I expect this to be a huge opportunity in the next few years. I am hoping Hemo secure a grant given the potential with CBR

But, the next update is likely to be the update on the third and final run of CAR-T - manufactured BY HEMO in HEMO safe labs. The only question is whether it will drop this week or next week.....

I was one of three shareholders that attended the AGM in FY22. I met a dutch investor and what seemed like someone who was a professional in either law or capital markets

It was a great experience tbh - even though it lasted less than 30 minutes. The directors who were in attendance had Vlad and Alexis on Video link and had a chance to ask questions and had a wonderful video tour of the new premises from Vlad.

I will go again this year

Great SP to finish - it seems like there has been good volume and support at 3.4/3.5 today and bodes well for a blue Monday

Keeps new investors very interested at this price

Keep an eye out later and Monday morning for BIG delayed trades.

Hemo are far too busy right now with CAR-T, CBR, conferences and a long bank holiday weekend to even think about a raise.

They have millions in the bank already from a dilutive raise a few years ago.

That diluted Team Sandler by c50%.

I do not see a raise - they will instead look at partnerships ans BIG upfront payments - as typical with up and coming Biotechs

All already has, nothing shared is new

It could 10 bag, in time, but wont get anywhere near that IMO for a few years - will need tangible progress on commercialisation to go that high.

For now, a mCap of £100m should be the target. (3 bags from here)

No, its a good thing. CAR-T therapies getting real traction and investment and why market predicted to grow to over £30BN
These are for a different type of cancer - Cancer is a simple word, but huge complexity of different conditions sit behind it

Or club together and Buy the Caribbean

So many buys showing up as sells (Red) - must be an MM tactic
They want shares i think - maybe more big orders to fill

Its Friday already.... 1 week nearer next RNS
Must be a great chance that the Sunday Papers pick up the Hemo story (CBR update) - may be worth a few of us copying in some of the sunday papers on Twitter
As already posted - a 3 day weekend in the USA - so good chance the US investors will look at this later today
Add into all that - the technical sound good (I'm only going on what the tech guys are saying) Golden Cross? Gap to Fill?

Hard to see when this will take a breather

WOW...someone bought £100k Hemo around 9am.....(That we know about - maybe more will be revealed)

I will do when I get there.... (2-3p to go)

Never apologise for taking profits.

Windy - be careful applying non-Biotech logic to this share

Some of the biggest Biotech success stories go years with no revenue and burn £100m a year to commercialise a drug - funding comes from partnerships with big upfront payments and milestone payments

This is the plan at Hemo - its getting to the tipping point where Big Pharma pushes the button. That could come anytime now for Hemo - probably on CarT when they get through Phase1/2 but could come sooner for CBR if it proves as game changing as the RNS suggest

I can vouch for Windy - Initially i found his posts difficult to read when we first crossed path on EVE.
But in time, I found his style very consistent and objective.
At times he will share a view that the SP will go down - but NEWSFLASH - that can happen
But i never found him (or her for that matter as I've never met them) to be rude, abusive or disruptive
All i would say to Windy is - please keep contextualising your posts if they are purely based on charts - it's up to the board then on how much credence they give to your view - most of us are 100% focused on the huge potential, tangible progress and ridiculously low Mcap. I'm interested in the SP in 3mths time, 1 years time, 5 years time etc (and very confident)

@Wyndy = hope you are well and hope EVE treated you well and you did not get burnt

Not sure how long HEMO has been on your radar. There is a high expectation of news in the coming weeks (or days) which is the catalyst for taking this higher.

I'm not going to dispute your technical insights - however, given the rize and characteristics of this share i would suggest its less reliable to rely on charts and far better to focus on the company's progress and the rich newsflow anticipated.

I certainly would not be buying or selling shares on the basis of RSI. It can be a useful tool to aid decision making, but not a key decision lever

I'm here to change my life - If Vlad and Hemo get even close to delivering there vision

You beat me to it Oh Whizzy Wise one

Agree - another good day with what feels like a nice balance between buys and sells and a string signal that it's consolidating at a decent level given the rapid growth.

The rest is unknown- I wonder if anyone notable is accumulating quietly? Or if Directors are buying given their recent optimism

LBE only hit my radar this week: it came to my attention having listened to Doc's podcast via Twitter - his first in a while and marks his formal return to being an active commentator of small caps. This bodes well as it seems to be part of a broader optimism that the end of the bear run for small caps in in sight.

Having been introduced to the company, it was interesting doing my research. From what i can deduce, the leadership are fairly highly regarded here, liquidity is NOT a medium concern with £9m in the bank, extended bank facility and a significant tax rebate incoming. It goes with the territory that the company has enjoyed mixed fortunes in the last 12 months in terms of discovery.

Like so many other small caps, the market has been tough on them leaving them very undervalued.

I've taken a small to moderate position (for me) and look forward to watching with interest

GLA